Literature DB >> 22070159

Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study.

P Malfertheiner1, M Nocon, M Vieth, M Stolte, D Jaspersen, H R Koelz, J Labenz, A Leodolter, T Lind, K Richter, S N Willich.   

Abstract

BACKGROUND: The evolution of gastro-oesophageal reflux disease (GERD) under current management options remains uncertain. AIM: To examine whether, depending on the initial presentation, non-erosive (NERD) and erosive reflux disease (ERD) without Barrett's oesophagus will progress to more severe disease under current routine care following the resolution of the initial condition.
METHODS: Patients with the primary symptom of heartburn were included at baseline, and stratified into non-erosive (NERD) and erosive reflux disease (ERD), LA grades A-D (Los Angeles classification). After a 2- to 8-week course with esomeprazole therapy to achieve endoscopic healing in ERD and symptom relief in NERD, patients were treated routinely at the discretion of their physician. We report oesophagitis status and the presence of endoscopic and confirmed Barrett's oesophagus after 5 years.
RESULTS: A total of 6215 patients were enrolled in the study of whom 2721 patients completed the 5-year follow-up. Progression, regression and stability of GERD severity were followed from baseline to 5 years. Only a few patients with NERD and mild/moderate ERD progressed to severe forms of ERD and even Barrett's oesophagus. Most patients remained stable or showed improvement in their oesophagitis; 5.9% of the NERD patients, 12.1% of LA grade A/B patients and 19.7% of LA grade C/D patients in whom no Barrett's oesophagus was recorded at baseline progressed to endoscopic or confirmed Barrett's oesophagus at 5 years.
CONCLUSION: Most GERD patients remain stable or improve over a 5-year observation period under current routine clinical care.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22070159     DOI: 10.1111/j.1365-2036.2011.04901.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  23 in total

Review 1.  Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation.

Authors:  Arne Kandulski; Peter Malfertheiner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-22       Impact factor: 46.802

Review 2.  [Barrett's esophagus].

Authors:  J Labenz
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

Review 3.  Magnetic sphincter augmentation for gastroesophageal reflux disease: review of clinical studies.

Authors:  Emanuele Asti; Alberto Aiolfi; Veronica Lazzari; Andrea Sironi; Matteo Porta; Luigi Bonavina
Journal:  Updates Surg       Date:  2018-07-18

Review 4.  Barrett's esophagus in 2016: From pathophysiology to treatment.

Authors:  Irene Martinucci; Nicola de Bortoli; Salvatore Russo; Lorenzo Bertani; Manuele Furnari; Anna Mokrowiecka; Ewa Malecka-Panas; Vincenzo Savarino; Edoardo Savarino; Santino Marchi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-05-06

5.  Necrotizing sialometaplasia-like change of the esophageal submucosal glands is associated with Barrett's esophagus.

Authors:  David R Braxton; Dana C Nickleach; Yuan Liu; Alton B Farris
Journal:  Virchows Arch       Date:  2014-05-27       Impact factor: 4.064

6.  Management of Esophageal Cancer.

Authors:  Steven R DeMeester
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-08

7.  Mind the Gap: Current Treatment Alternatives for GERD Patients Failing Medical Treatment and Not Ready for a Fundoplication.

Authors:  Phuong Huynh; Vani Konda; Suchakree Sanguansataya; Marc A Ward; Steven G Leeds
Journal:  Surg Laparosc Endosc Percutan Tech       Date:  2020-12-16       Impact factor: 1.719

8.  EAES recommendations for the management of gastroesophageal reflux disease.

Authors:  Karl Hermann Fuchs; Benjamin Babic; Wolfram Breithaupt; Bernard Dallemagne; Abe Fingerhut; Edgar Furnee; Frank Granderath; Peter Horvath; Peter Kardos; Rudolph Pointner; Edoardo Savarino; Maud Van Herwaarden-Lindeboom; Giovanni Zaninotto
Journal:  Surg Endosc       Date:  2014-05-02       Impact factor: 4.584

9.  Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes.

Authors:  Kerry B Dunbar; Agoston T Agoston; Robert D Odze; Xiaofang Huo; Thai H Pham; Daisha J Cipher; Donald O Castell; Robert M Genta; Rhonda F Souza; Stuart J Spechler
Journal:  JAMA       Date:  2016-05-17       Impact factor: 56.272

10.  LINX(®) Reflux Management System in chronic gastroesophageal reflux: a novel effective technology for restoring the natural barrier to reflux.

Authors:  Luigi Bonavina; Greta Saino; John C Lipham; Tom R Demeester
Journal:  Therap Adv Gastroenterol       Date:  2013-07       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.